Decreased Expression of Inhibitor of Caspase-Activated DNase (ICAD) in Renal Cell Carcinoma –Tissue Microarray of Human Samples
Main Article Content
Keywords
apoptosis, ICAD, kidney cancer, renal cell carcinoma, tissue microarray
Abstract
Although primary localised tumours of renal cell carcinoma (RCC) can be treated relatively successfully with surgery, metastatic RCC has poor prognosis because of late diagnosis and resistance to therapies. In the present study, we were interested in profiling the protein expression of “inhibitor of caspase-activated DNase” (ICAD), an apoptosis inhibitor, in kidney cancer and its paired normal kidney. Immunohistochemistry with automated batch staining and morphometry using digital pathology were used to compare ICAD in 121 RCC specimens with their paired normal kidney tissue. Tissue microarray of formalin-fixed, paraffin-embedded archival tissue was used. Intensity and localisation of ICAD were compared between normal and cancer samples, and against grading within the cancers. The results demonstrated that, in this cohort, ICAD was highly expressed in the proximal tubular epithelium of normal kidney, and significantly decreased in clear cell RCC tissue (p < 0.05) as well as other subtypes of RCC (p < 0.01) compared with normal kidney. There was a tendency towards nuclear localisation of ICAD in clear cell RCC, but not in other subtypes of RCC. No significant association was found between ICAD intensity and grade of RCC. In summary, down-regulation of ICAD occurs in RCC. ICAD normally inhibits DNA fragmentation and apoptosis; thus, its down-regulation was unexpected in a cancer known for its resistance to apoptosis. However, these RCC samples were from primary, not metastatic, RCC sites, and down-regulated ICAD may be part of a progressive pathway that promotes RCC metastasis.
References
2. Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60(4):615–21. http://dx.doi.org/10.1016/j.eururo.2011.06.049
3. Ng KL, Rajandram R, Morais C, Yap NY, Samaratunga H, Gobe GC, et al. Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem? J Clin Pathol. 2014;67(2):97–104. http://dx.doi.org/10.1136/jclinpath-2013-201895
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. http://dx.doi.org/10.1016/j.cell.2011.02.013
6. Boon SS, Sim SP. Inhibitor of caspase-activated DNase expression enhances caspase-activated DNase expression and inhibits oxidative stress-induced chromosome breaks at the mixed lineage leukaemia gene in nasopharyngeal carcinoma cells. Cancer Cell Int. 2015;15:54. http://dx.doi.org/10.1186/s12935-015-0205-1
7. Nagata S, Nagase H, Kawane K, Mukae N, Fukuyama H. Degradation of chromosomal DNA during apoptosis. Cell Death Differ. 2003;10(1):108–16. http://dx.doi.org/10.1038/sj.cdd.4401161
8. Kawane K, Nagata S. Nucleases in programmed cell death. Methods Enzymol. 2008;442:271–87. http://dx.doi.org/10.1016/S0076-6879(08)01414-6
9. Inohara N, Koseki T, Chen S, Wu X, Nunez G. CIDE, a novel family of cell death activators with homology to the 45 kDa subunit of the DNA fragmentation factor. EMBO J. 1998;17(9):2526–33. http://dx.doi.org/10.1093/emboj/17.9.2526
10. Erdtmann L, Franck N, Lerat H, Le Seyec J, Gilot D, Cannie I, et al. The hepatitis C virus NS2 protein is an inhibitor of CIDE-B-induced apoptosis. J Biol Chem. 2003;278(20):18256–64. http://dx.doi.org/10.1074/jbc.M209732200
11. Hara S, Miyake H, Arakawa S, Kamidono S, Hara I. Overexpression of inhibitor of caspase 3 activated deoxyribonuclease in human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy in vivo. J Urol. 2001;166(6):2491–4.
12. Rajandram R, Pat BK, Li J, Johnson DW, Gobe GC. Expression of apoptotic tumour necrosis factor receptor-associated factor, caspase recruitment domain and cell death-inducing DFF-45 effector genes in therapy-treated renal cell carcinoma. Nephrology (Carlton). 2009;14(2):205–12. http://dx.doi.org/10.1111/j.1440-1797.2008.01027.x
13. Zhdanov DD, Fahmi T, Wang X, Apostolov EO, Sokolov NN, Javadov S, et al. Regulation of apoptotic endonucleases by EndoG. DNA Cell Biol. 2015;34(5):316–26. http://dx.doi.org/10.1089/dna.2014.2772
14. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res. 2000;256(1):12–8. http://dx.doi.org/10.1006/excr.2000.4834
15. WHO. Pathology & Genetics: Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.
16. Rioux-Leclercq N, Ferran A, Mahul A, Argani P, Billis A, Bonsib S, et al. [Renal tumors: The International Society of Urologic Pathology (ISUP) 2012 consensus conference recommendations]. Ann Pathol. 2014;34(6):448–61.
17. Rajandram R, Bennett NC, Wang Z, Perry-Keene J, Vesey DA, Johnson DW, et al. Patient samples of renal cell carcinoma show reduced expression of TRAF1 compared with normal kidney and functional studies in vitro indicate TRAF1 promotes apoptosis: potential for targeted therapy. Pathology. 2012;44(5):453–9. http://dx.doi.org/10.1097/PAT.0b013e3283557748
18. Nagata S. DNA degradation in development and programmed cell death. Ann Rev Immunol. 2005;23:853–75. http://dx.doi.org/10.1146/annurev.immunol.23.021704.115811
19. Masuoka F, Shiraishi T, Ichinose M, Mineta T, Tabuchi K. Expression of ICAD-L and ICAD-S in human brain tumor and its cleavage upon activation of apoptosis by anti-Fas antibody. Jpn J Cancer Res. 2001;92(7):806–12.
20. Charrier L, Jarry A, Toquet C, Bou-Hanna C, Chedorge M, Denis M, et al. Growth phase-dependent expression of ICAD-L/DFF45 modulates the pattern of apoptosis in human colonic cancer cells. Cancer Res. 2002;62(7):2169–74.
21. Xerri L, Palmerini F, Devilard E, Defrance T, Bouabdallah R, Hassoun J, et al. Frequent nuclear localization of ICAD and cytoplasmic co-expression of caspase-8 and caspase-3 in human lymphomas. J Pathol. 2000;192(2):194–202. http://dx.doi.org/10.1002/1096-9896(2000)9999:9999<::AID-PATH685>3.0.CO;2-M
22. Chiang MC, Ashraf QM, Mishra OP, Delivoria-Papadopoulos M. Mechanism of DNA fragmentation during hypoxia in the cerebral cortex of newborn piglets. Neurochem Res. 2008;33(7):1232–7. http://dx.doi.org/10.1007/s11064-007-9574-8
23. Samejima K, Earnshaw WC. ICAD/DFF regulator of apoptotic nuclease is nuclear. Exp Cell Res. 1998;243(2):453–9. http://dx.doi.org/10.1006/excr.1998.4212
24. Scholz SR, Korn C, Gimadutdinow O, Knoblauch M, Pingoud A, Meiss G. The effect of ICAD-S on the formation and intracellular distribution of a nucleolytically active caspase-activated DNase. Nucleic Acids Res. 2002;30(14):3045–51.
25. Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, et al. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer. 2006;106(8):1677–84. http://dx.doi.org/10.1002/cncr.21783
26. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Med. 1998;4(7):844–7.
27. Waterworth A, Horgan K, Speirs V, Hanby AM. Tissue microarrays - big potential from small samples (Review). Int J Oncol. 2004;25(1):167–71.
28. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nature Med. 2002;8(11):1323–7. http://dx.doi.org/10.1038/nm791
29. Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis. 2000;21(11):2235–42. http://dx.doi.org/10.1002/1522-2683(20000601)21:11<2235::AID-ELPS2235>3.0.CO;2-A
30. Skinnider BF, Amin MB. An immunohistochemical approach to the differential diagnosis of renal tumors. Semin Diagn Pathol. 2005;22(1):51–68.
31. Englert CR, Baibakov GV, Emmert-Buck MR. Layered expression scanning: Rapid molecular profiling of tumor samples. Cancer Res. 2000;60(6):1526–30.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.